This is a phase 2 study to investigate the safety and efficacy of PAC-14028 cream in Atopic Dermatitis patients.
PAC-14028 Cream (0.1%, 0.3%, 1.0%) or placebo will be treated to Mild to Moderate Atopic Dermatitis patients twice daily for 8 weeks.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
192
Topical application
Topical application
Topical application
Chung-ang University Hospital
Seoul, South Korea
Success rate of Investigator's Global Assessment (IGA)
percent of patients with IGA score of 0 (clear) or 1 (almost clear)
Time frame: 8 weeks
Success rate of Investigator's Global Assessment (IGA)
percent of patients with IGA score of 0 (clear) or 1 (almost clear)
Time frame: 1, 3, 6 week(s)
Change in SCORAD (Severity Score of Atopic Dermatitis)
Time frame: 1, 3, 6, 8 week(s)
% Change in Eczema Area and Severity Index (EASI)
Time frame: 1, 3, 6, 8 week(s)
Success rate of Pruritus Severity score
Time frame: 1, 3, 6, 8 week(s)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Topical application